Bio-Rad Laboratories, Inc.

Total Valuation

Bio-Rad Laboratories, Inc. carries a market capitalization of 10.39B, placing it among publicly traded companies globally. Its enterprise value stands at 7.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Bio-Rad Laboratories, Inc. currently has 26.74M shares outstanding.

Valuation Ratios

Bio-Rad Laboratories, Inc. trades at a trailing price-to-earnings ratio of 35.51. The price-to-sales ratio is 3.05, and the price-to-book ratio stands at 1.09.

Enterprise Valuation

On an enterprise value basis, Bio-Rad Laboratories, Inc. trades at an EV/EBITDA multiple of 19.33 and an EV/FCF ratio of 11.47. The EV/Sales ratio of 2.94 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 33.86 provides insight into valuation relative to core operating earnings.

Financial Position

Bio-Rad Laboratories, Inc. maintains a current ratio of 3.14, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 19.10, indicating elevated leverage, while an interest coverage ratio of 8.06 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Bio-Rad Laboratories, Inc. posts a return on equity of 3.11 and a return on invested capital of 1.66.

Taxes

Over the trailing twelve months, Bio-Rad Laboratories, Inc. has paid 128.00M in income taxes, reflecting an effective tax rate of 36.53.

Stock Price Statistics

Bio-Rad Laboratories, Inc.'s stock has gained approximately 32.96715% over the past 52 weeks. The 50-day moving average sits at 336.20, while the 200-day moving average is 302.00.

Income Statement

Over the trailing twelve months, Bio-Rad Laboratories, Inc. generated 2.59B in revenue and converted that into 222.40M in net income, yielding earnings per share of 8.26. EBITDA reached 393.20M, while operating income came in at 224.50M.

Balance Sheet

Bio-Rad Laboratories, Inc. holds 1.62B in cash and equivalents against 1.37B in total debt, resulting in a net debt position of 686.70M. Total book value stands at 7.17B, with working capital of 2.06B providing operational flexibility.

Cash Flow

Bio-Rad Laboratories, Inc. produced 492.60M in operating cash flow over the past twelve months. After subtracting -139.50M in capital expenditures, free cash flow totaled 353.10M - equivalent to 13.13 per share.

Margins

Bio-Rad Laboratories, Inc. operates with a gross margin of 51.90, reflecting its pricing power and cost economics. The operating margin of 8.67 and net profit margin of 8.59 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Bio-Rad Laboratories, Inc.'s most recent stock split took place on March 8, 2002 with a 1:2 split ratio.

Scores

Bio-Rad Laboratories, Inc. posts an Altman Z-Score of 3.32, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.